Abstract
Erythropoietin (Epo) is a glycoprotein hormone that is the prime regulator of erythropoiesis. Recombinant Epo is a highly effective pharmaceutical used to correct anemias associated with renal insufficiency, cancer and other diseases. Efforts to increase its efficacy in vivo by manipulating the proteins structure have met with some success, and novel Epo-like agents are in development. Additionally, efforts to create Epo mimetic agents are underway, as is the design of agents to increase endogenous production. Because Epo has tissue protective actions outside of erythropoiesis, other designs have focused on producing erythropoietically inactive molecules that still retain extra-hematopoietic activity. The demonstration that Epo can trigger signaling in some cancer cells with, potentially, adverse effects on patient health has raised warning signs in the medical community and has gained the attention of regulatory authorities.
Keywords: Erythropoietin, erythropoietin receptor, glycosylation, pegylation, fusion proteins, mimetics, heteroreceptor, cancer
Current Pharmaceutical Design
Title: Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Volume: 14 Issue: 13
Author(s): N. Debeljak and A. J. Sytkowski
Affiliation:
Keywords: Erythropoietin, erythropoietin receptor, glycosylation, pegylation, fusion proteins, mimetics, heteroreceptor, cancer
Abstract: Erythropoietin (Epo) is a glycoprotein hormone that is the prime regulator of erythropoiesis. Recombinant Epo is a highly effective pharmaceutical used to correct anemias associated with renal insufficiency, cancer and other diseases. Efforts to increase its efficacy in vivo by manipulating the proteins structure have met with some success, and novel Epo-like agents are in development. Additionally, efforts to create Epo mimetic agents are underway, as is the design of agents to increase endogenous production. Because Epo has tissue protective actions outside of erythropoiesis, other designs have focused on producing erythropoietically inactive molecules that still retain extra-hematopoietic activity. The demonstration that Epo can trigger signaling in some cancer cells with, potentially, adverse effects on patient health has raised warning signs in the medical community and has gained the attention of regulatory authorities.
Export Options
About this article
Cite this article as:
Debeljak N. and Sytkowski J. A., Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives, Current Pharmaceutical Design 2008; 14 (13) . https://dx.doi.org/10.2174/138161208799316393
DOI https://dx.doi.org/10.2174/138161208799316393 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Host Immune Responses to Aeromonas Virulence Factors
Current Immunology Reviews (Discontinued) Image Fusion of Diagnostic Ultrasound with Other Modalities
Current Medical Imaging Melanoma
Current Cancer Therapy Reviews Nanoparticles in Cancer
Current Radiopharmaceuticals Comparison Between the Maximum Standard Uptake Value and the Ratio of Lymph Node to Primary Tumor Attenuation in Head and Neck Cancers: A Prospective Study
Current Medical Imaging MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future
Current Pharmaceutical Design Modulation of DNA Damage Checkpoint; Patenting and Possible Application for Cancer Medicine
Recent Patents on DNA & Gene Sequences Advanced Micro-Nano-Bio Systems for Future Targeted Therapies
Current Nanoscience Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Current Gene Therapy Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells
Current Gene Therapy Genitourinary Tract Tumors in Children: An Update
Current Pediatric Reviews Exploring Mechanisms of MicroRNA Downregulation in Cancer
MicroRNA Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers
Anti-Cancer Agents in Medicinal Chemistry Design, Synthesis and Biological Evaluation of Salicylamide Analogues as Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Letters in Drug Design & Discovery Erythropoietin and Oxidative Stress
Current Neurovascular Research The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Alterations in Homocysteine Metabolism Among Alcohol Dependent Patients - Clinical, Pathobiochemical and Genetic Aspects
Current Drug Abuse Reviews Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design